152 related articles for article (PubMed ID: 38702528)
1. Real-World Clinical, Psychosocial, and Economic Burden of Atopic Dermatitis: Results From the ESSENTIAL AD Multicountry Study.
Gkalpakiotis S; Kannenberg S; Kingo K; Nada HR; Rakhmatulina MR; Lesiak A; Nicolescu AC; Darlenski R; Masri A; Zhou L; Albuquerque T; Hammad S; Almasry I
Dermatol Ther (Heidelb); 2024 May; 14(5):1173-1187. PubMed ID: 38702528
[TBL] [Abstract][Full Text] [Related]
2. Real-world clinical, psychosocial and economic burden of atopic dermatitis: Results from a multicountry study.
Eyerich K; Gooderham MJ; Silvestre JF; Shumack SP; Mendes-Bastos P; Aoki V; Ortoncelli M; Silverberg JI; Teixeira HD; Chen SH; Calimlim BM; Takemoto S; Sancho C; Fritz B; Irvine AD
J Eur Acad Dermatol Venereol; 2024 Feb; 38(2):340-353. PubMed ID: 37669868
[TBL] [Abstract][Full Text] [Related]
3. Disease burden among patients with atopic dermatitis treated with systemic therapy for 4-12 months: results from the CorEvitas Atopic Dermatitis Registry.
Silverberg JI; Pierce E; Feely M; Atwater AR; Schrader A; Jones EA; Dave SS; Simpson EL
J Dermatolog Treat; 2023 Dec; 34(1):2246601. PubMed ID: 37691405
[TBL] [Abstract][Full Text] [Related]
4. Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin types.
Bosma AL; Ouwerkerk W; Heidema MJ; Prieto-Merino D; Ardern-Jones MR; Beattie P; Brown SJ; Ingram JR; Irvine AD; Ogg G; Patel P; Reynolds NJ; Hearn RMR; Wan M; Warren RB; Woolf RT; Hyseni AM; Gerbens LAA; Spuls PI; Flohr C; Middelkamp-Hup MA;
JAAD Int; 2023 Mar; 10():14-24. PubMed ID: 36387062
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial.
Simpson EL; Silverberg JI; Thyssen JP; Viguier M; Thaçi D; de Bruin-Weller M; Weidinger S; Chan G; DiBonaventura M; Biswas P; Feeney C; Koulias C; Cork MJ
Am J Clin Dermatol; 2023 Jul; 24(4):609-621. PubMed ID: 37213005
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand: A cross sectional study from the TARGET-DERM AD cohort.
Silverberg JI; Simpson B; Abuabara K; Guttman-Yassky E; Calimlim B; Wegzyn C; Krueger W; Gamelli A; Munoz B; Faller RW; Crawford JM; Grada A; Eichenfield LF;
J Am Acad Dermatol; 2023 Sep; 89(3):519-528. PubMed ID: 37150299
[TBL] [Abstract][Full Text] [Related]
7. Inadequate Disease Control, Treatment Dissatisfaction, and Quality-of-Life Impairments Among US Patients Receiving Topical Therapy for Atopic Dermatitis.
Anderson P; Austin J; Lofland JH; Piercy J; Joish VN
Dermatol Ther (Heidelb); 2021 Oct; 11(5):1571-1585. PubMed ID: 34268709
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Patient-Oriented Eczema Measure and Patient-Oriented Scoring Atopic Dermatitis vs Eczema Area and Severity Index and other measures of atopic dermatitis: A validation study.
Silverberg JI; Lei D; Yousaf M; Janmohamed SR; Vakharia PP; Chopra R; Chavda R; Gabriel S; Patel KR; Singam V; Kantor R; Hsu DY
Ann Allergy Asthma Immunol; 2020 Jul; 125(1):78-83. PubMed ID: 32199977
[TBL] [Abstract][Full Text] [Related]
9. Association of Inadequately Controlled Disease and Disease Severity With Patient-Reported Disease Burden in Adults With Atopic Dermatitis.
Simpson EL; Guttman-Yassky E; Margolis DJ; Feldman SR; Qureshi A; Hata T; Mastey V; Wei W; Eckert L; Chao J; Arnold RJG; Yu T; Vekeman F; Suárez-Fariñas M; Gadkari A
JAMA Dermatol; 2018 Aug; 154(8):903-912. PubMed ID: 29971354
[TBL] [Abstract][Full Text] [Related]
10. Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials.
Griffiths C; de Bruin-Weller M; Deleuran M; Fargnoli MC; Staumont-Sallé D; Hong CH; Sánchez-Carazo J; Foley P; Seo SJ; Msihid J; Chen Z; Cyr SL; Rossi AB
Dermatol Ther (Heidelb); 2021 Aug; 11(4):1357-1372. PubMed ID: 34142350
[TBL] [Abstract][Full Text] [Related]
11. Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study.
Silverberg JI; Gelfand JM; Margolis DJ; Boguniewicz M; Fonacier L; Grayson MH; Simpson EL; Ong PY; Chiesa Fuxench ZC
Ann Allergy Asthma Immunol; 2018 Sep; 121(3):340-347. PubMed ID: 30025911
[TBL] [Abstract][Full Text] [Related]
12. Humanistic and Economic Burden of Atopic Dermatitis for Adults and Adolescents in the Middle East and Africa Region.
Elezbawy B; Fasseeh AN; Fouly E; Tannira M; Dalle H; Aderian S; Abu Esba LC; Al Abdulkarim H; Ammoury A; Altawil E; Al Turaiki A; Albreiki F; Al-Haddab M; Al-Lafi A; Alowayesh M; Al-Sheikh A; Elsayed M; Elshamy A; Eshmawi M; Farag A; Hamadah I; Hedibel M; Kannenberg S; Karam R; Metni M; Raboobee N; Steinhoff M; Abaza S; Farghaly M; Kaló Z
Dermatol Ther (Heidelb); 2023 Jan; 13(1):131-146. PubMed ID: 36445612
[TBL] [Abstract][Full Text] [Related]
13. Release of Cervical Muscle Tension Improves Psychological Stress and Symptoms of Moderate-to-Severe Atopic Dermatitis: a Case Series with 20 Patients.
Hosono S; Fujita K; Nimura A; Akita K
Dermatol Ther (Heidelb); 2022 Oct; 12(10):2383-2395. PubMed ID: 36129669
[TBL] [Abstract][Full Text] [Related]
14. Real-World Effectiveness of Dupilumab in Adult and Adolescent Patients with Atopic Dermatitis: 2-Year Interim Data from the PROSE Registry.
Simpson EL; Lockshin B; Lee LW; Chen Z; Daoud M; Korotzer A
Dermatol Ther (Heidelb); 2024 Jan; 14(1):261-270. PubMed ID: 38175364
[TBL] [Abstract][Full Text] [Related]
15. What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? A prospective observational study.
Silverberg JI; Lei D; Yousaf M; Janmohamed SR; Vakharia PP; Chopra R; Chavda R; Gabriel S; Patel KR; Singam V; Kantor R; Hsu DY
Br J Dermatol; 2021 May; 184(5):888-895. PubMed ID: 32959390
[TBL] [Abstract][Full Text] [Related]
16. The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and Canada.
de Bruin-Weller M; Gadkari A; Auziere S; Simpson EL; Puig L; Barbarot S; Girolomoni G; Papp K; Pink AE; Saba G; Werfel T; Eckert L
J Eur Acad Dermatol Venereol; 2020 May; 34(5):1026-1036. PubMed ID: 31587373
[TBL] [Abstract][Full Text] [Related]
17. Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study.
Alexis A; de Bruin-Weller M; Weidinger S; Soong W; Barbarot S; Ionita I; Zhang F; Valdez H; Clibborn C; Yin N
Dermatol Ther (Heidelb); 2022 Mar; 12(3):771-785. PubMed ID: 35297025
[TBL] [Abstract][Full Text] [Related]
18. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis.
Chopra R; Vakharia PP; Sacotte R; Patel N; Immaneni S; White T; Kantor R; Hsu DY; Silverberg JI
Br J Dermatol; 2017 Nov; 177(5):1316-1321. PubMed ID: 28485036
[TBL] [Abstract][Full Text] [Related]
19. Frequency and influence of "not relevant" responses on the Dermatology Life Quality Index among adults with atopic dermatitis.
Barbieri JS; Chiesa Fuxench ZC; Shin DB; Takeshita J
Qual Life Res; 2021 Jun; 30(6):1705-1713. PubMed ID: 33538979
[TBL] [Abstract][Full Text] [Related]
20. [Decreased professional performance and quality of life in patients with moderate-to-severe atopic eczema : Results from the German atopic eczema registry TREATgermany].
Haufe E; Abraham S; Heratizadeh A; Harder I; Zink A; Weisshaar E; Kleinheinz A; von Kiedrowski R; Worm M; Bell M; Wollenberg A; Neubert K; Staubach-Renz P; Hilgers M; Bieber T; Fell I; Homey B; Effendy I; Mempel M; Schäkel K; Beissert S; Weidinger S; Werfel T; Schmitt J
Hautarzt; 2018 Oct; 69(10):815-824. PubMed ID: 30191254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
